About pemigatinib
Fibroblast growth factor receptor inhibitor
Used for
- Treats certain previously treated, advanced bile duct cancers with FGFR2 fusions or rearrangements
- Treats certain adults with myeloid or lymphoid cancers involving FGFR1 rearrangements
Usual adult dose
Bile duct cancer: 13.5 mg by mouth once daily for 14 days, then 7 days off. FGFR1 cancers: 13.5 mg once daily continuously.
Common side effects
- High phosphate levels
- Changes in nails, hair, or skin
- Dry eyes or mouth
- Diarrhea, fatigue, or mouth sores
Important warnings
- Eye problems, including retinal detachment, can occur; eye checks are required
- High phosphate can cause soft-tissue mineral deposits; blood tests and dietary management may be needed
- Report new vision changes promptly
- Doses may need adjustment for liver or kidney problems
Pregnancy
May harm an unborn baby. Pregnancy testing and effective contraception are recommended during treatment and for one week afterward.
Breastfeeding
Avoid breastfeeding during treatment and for one week after the last dose.
Interactions
- Strong or moderate CYP3A inhibitors can increase pemigatinib exposure
- Strong or moderate CYP3A inducers can reduce pemigatinib exposure
- Acid-reducing medicines may affect absorption; follow prescribing instructions
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.